Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1 Double-blind, Dose-escalation, Clinical Trial to Evaluate the Safety, Tolerability and Immunogenicity of the Ebola Adenovirus Vector Vaccine (Ad5-EBOV) in Healthy Adults in China

Next Previous
Trial Profile

A Phase 1 Double-blind, Dose-escalation, Clinical Trial to Evaluate the Safety, Tolerability and Immunogenicity of the Ebola Adenovirus Vector Vaccine (Ad5-EBOV) in Healthy Adults in China

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 31 Aug 2015

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Ad5 EBOV DNA vaccine (Primary)
  • Indications Ebola virus infections
  • Focus Adverse reactions; Pharmacodynamics
  • Sponsors Tianjin CanSino Biotechnology

Most Recent Events

  • 06 Jun 2015 Results published in the Lancet.
  • 06 Jun 2015 Status changed from active, no longer recruiting to completed, as reported in The Lancet.
  • 06 Jun 2015 Primary endpoint has been met. (Specific anti-EBOV antibody responses to the Ebola Zaire vaccine (Ad5-EBOV).)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top